IFNG and vitiligo: Other biomarkers, proposed to be predictive for response to immunotherapy with check-point inhibitors [84], such as PD-1/PD-L1 or CTLA-4 expression, presence of an IFN-γ signature, or augmented inflammatory cytokines, are also hallmarks of active vitiligo (Table 1).